{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:12Z","timestamp":1794047472151,"version":"4.8.0"},"reference-count":56,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"11","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Multiple myeloma (MM) remains an incurable hematologic malignancy. Despite tremendous advances in the treatment of this disease, about 10% of patients still have very poor outcomes with a median overall survival of less than 24 months. Our study aimed to underscore the critical mechanisms pertaining to rapid disease progression and provide novel therapeutic choices for these ultrahigh-risk patients. We utilized single-cell transcriptomic sequencing to dissect the characteristic bone marrow niche of patients who survived less than 2 years (EM24). Notably, enrichment of a LILRB4high pre-mature plasma-cell cluster was observed in EM24 patients compared to patients with durable remission. This cluster exhibited aggressive proliferation and a drug-resistance phenotype. High levels of LILRB4 promoted MM clonogenicity and progression. Clinically, high expression of LILRB4 was correlated with poor prognosis in both newly diagnosed MM patients and relapsed\/ refractory MM patients. ATAC-sequencing analysis identified that pronounced chromosomal accessibility caused the elevation of LILRB4 on MM cells. CRISPR-Cas9 deletion of LILRB4 alleviated the growth of MM cells, inhibited the immunosuppressive function of myeloid-derived suppressive cells (MDSC), and further rescued T-cell dysfunction in the MM microenvironment. Greater infiltration of MDSC was observed in EM24 patients. We therefore generated an innovative T-cell receptor-based chimeric antigen receptor T cell, LILRB4-STAR-T. Cytotoxicity experiments demonstrated that LILRB4-STAR-T cells efficaciously eliminated tumor cells and impeded MDSC function. In conclusion, our study elucidates that LILRB4 is an ideal biomarker and promising immunotherapy target for high-risk MM. LILRB4-STAR-T-cell immunotherapy is promising against both tumor cells and the immunosuppressive tumor microenvironment in MM.<\/jats:p>","DOI":"10.3324\/haematol.2024.285099","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T08:24:42Z","timestamp":1717057482000},"page":"3650-3669","source":"Crossref","is-referenced-by-count":11,"title":["LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma"],"prefix":"10.3324","volume":"109","author":[{"given":"Lixin","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangshuo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"68553","doi-asserted-by":"crossref","unstructured":"Bazarbachi AH, Al Hamed R, Malard F. Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia. 2019; 33(10):2343-2357.","DOI":"10.1038\/s41375-019-0561-2"},{"key":"68554","doi-asserted-by":"crossref","unstructured":"Kumar S, Baizer L, Callander NS. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer J. 2022; 12(6):98.","DOI":"10.1038\/s41408-022-00695-5"},{"key":"68555","doi-asserted-by":"crossref","unstructured":"Cowan AJ, Green DJ, Kwok M. Diagnosis and management of multiple myeloma: a review. JAMA. 2022; 327(5):464-477.","DOI":"10.1001\/jama.2022.0003"},{"key":"68556","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016; 127(24):2955-2962.","DOI":"10.1182\/blood-2016-01-631200"},{"key":"68557","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo R, S\u00e1inz J, Mart\u00ednez-L\u00f3pez J. Early mortality in multiple myeloma: the time-dependent impact of comorbidity: a population-based study in 621 real-life patients. Am J Hematol. 2016; 91(7):700-704.","DOI":"10.1002\/ajh.24389"},{"key":"68558","doi-asserted-by":"crossref","unstructured":"Terebelo H, Srinivasan S, Narang M. Recognition of early mortality in multiple myeloma by a prediction matrix. Am J Hematol. 2017; 92(9):915-923.","DOI":"10.1002\/ajh.24796"},{"key":"68559","doi-asserted-by":"crossref","unstructured":"Neuse CJ, Lomas OC, Schliemann C. Genome instability in multiple myeloma. Leukemia. 2020; 34(11):2887-2897.","DOI":"10.1038\/s41375-020-0921-y"},{"key":"68560","doi-asserted-by":"crossref","unstructured":"Tirier SM, Mallm JP, Steiger S. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nat Commun. 2021; 12(1):6960.","DOI":"10.1038\/s41467-021-26951-z"},{"key":"68561","doi-asserted-by":"crossref","unstructured":"Kumar SK, Rajkumar SV. The multiple myelomas - current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018; 15(7):409-421.","DOI":"10.1038\/s41571-018-0018-y"},{"key":"68562","doi-asserted-by":"crossref","unstructured":"Yan Y, Qin X, Liu J. Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at singlecell level by QM-FISH. Blood Adv. 2022; 6(2):441-451.","DOI":"10.1182\/bloodadvances.2021004992"},{"key":"68563","doi-asserted-by":"crossref","unstructured":"Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017; 17(9):543-556.","DOI":"10.1038\/nrc.2017.63"},{"key":"68564","doi-asserted-by":"crossref","unstructured":"Liu R, Gao Q, Foltz SM. Co-evolution of tumor and immune cells during progression of multiple myeloma. Nat Commun. 2021; 12(1):2559.","DOI":"10.1038\/s41467-021-22804-x"},{"key":"68565","doi-asserted-by":"crossref","unstructured":"Dutta AK, Alberge JB, Sklavenitis-Pistofidis R. Single-cell profiling of tumour evolution in multiple myeloma -opportunities for precision medicine. Nat Rev Clin Oncol. 2022; 19(4):223-236.","DOI":"10.1038\/s41571-021-00593-y"},{"key":"68566","doi-asserted-by":"crossref","unstructured":"Lv J, Sun H, Gong L. Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma. Front Immunol. 2022; 13:1077768.","DOI":"10.3389\/fimmu.2022.1077768"},{"key":"68567","doi-asserted-by":"crossref","unstructured":"Zavidij O, Haradhvala NJ, Mouhieddine TH. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020; 1(5):493-506.","DOI":"10.1038\/s43018-020-0053-3"},{"key":"68568","doi-asserted-by":"crossref","unstructured":"Hao M, Zhang L, An G. Suppressing miRNA-15a\/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. J Hematol Oncol. 2011; 4:37.","DOI":"10.1186\/1756-8722-4-37"},{"key":"68569","doi-asserted-by":"crossref","unstructured":"Hao M, Zhang L, An G. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma. 2011; 52(9):1787-1794.","DOI":"10.3109\/10428194.2011.576791"},{"key":"68570","doi-asserted-by":"crossref","unstructured":"Sun H, Fang T, Wang T. Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenstr\u00f6m macroglobulinemia. J Transl Med. 2022; 20(1):576.","DOI":"10.1186\/s12967-022-03798-6"},{"key":"68571","doi-asserted-by":"crossref","unstructured":"Jia Y, Zhou J, Tan TK. Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma. Blood Cancer J. 2021; 11(2):32.","DOI":"10.1038\/s41408-021-00421-7"},{"key":"68572","doi-asserted-by":"crossref","unstructured":"Agarwal P, Alzrigat M, P\u00e1rraga AA. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target. Oncotarget. 2016; 7(6):6809-6823.","DOI":"10.18632\/oncotarget.6843"},{"key":"68573","doi-asserted-by":"crossref","unstructured":"Yu G, Wang LG, He QY. ChIPseeker: an R\/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics. 2015; 31(14):2382-2383.","DOI":"10.1093\/bioinformatics\/btv145"},{"key":"68574","doi-asserted-by":"crossref","unstructured":"Liu Y, Liu G, Wang J. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci Transl Med. 2021; 13(586):eabb5191.","DOI":"10.1126\/scitranslmed.abb5191"},{"key":"68575","doi-asserted-by":"crossref","unstructured":"An G, Xu Y, Shi L. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica. 2014; 99(2):353-359.","DOI":"10.3324\/haematol.2013.088211"},{"key":"68576","doi-asserted-by":"crossref","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022; 97(8):1086-1107.","DOI":"10.1002\/ajh.26590"},{"key":"68577","doi-asserted-by":"crossref","unstructured":"Liu L, Yu Z, Cheng H. Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment. Sci Rep. 2020; 10(1):20508.","DOI":"10.1038\/s41598-020-77450-y"},{"key":"68578","doi-asserted-by":"crossref","unstructured":"Gao M, Bai H, Jethava Y. Identification and characterization of tumor-initiating cells in multiple myeloma. J Natl Cancer Inst. 2020; 112(5):507-515.","DOI":"10.1093\/jnci\/djz159"},{"key":"68579","doi-asserted-by":"crossref","unstructured":"Caron M, St-Onge P, Sontag T. Single-cell analysis of childhood leukemia reveals a link between developmental states and ribosomal protein expression as a source of intra-individual heterogeneity. Sci Rep. 2020; 10(1):8079.","DOI":"10.1038\/s41598-020-64929-x"},{"key":"68580","doi-asserted-by":"crossref","unstructured":"Mehtonen J, Teppo S, Lahnalampi M. Single cell characterization of B-lymphoid differentiation and leukemic cell states during chemotherapy in ETV6-RUNX1-positive pediatric leukemia identifies drug-targetable transcription factor activities. Genome Med. 2020; 12(1):99.","DOI":"10.1186\/s13073-020-00799-2"},{"key":"68581","doi-asserted-by":"crossref","unstructured":"Zhang Y, Wang S, Zhang J. Elucidating minimal residual disease of paediatric B-cell acute lymphoblastic leukaemia by single-cell analysis. Nat Cell Biol. 2022; 24(2):242-252.","DOI":"10.1038\/s41556-021-00814-7"},{"key":"68582","doi-asserted-by":"crossref","unstructured":"Shaughnessy JD, Zhan F, Burington BE. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007; 109(6):2276-2284.","DOI":"10.1182\/blood-2006-07-038430"},{"key":"68583","doi-asserted-by":"crossref","unstructured":"Zhou W, Yang Y, Xia J. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 2013; 23(1):48-62.","DOI":"10.1016\/j.ccr.2012.12.001"},{"key":"68584","doi-asserted-by":"crossref","unstructured":"Hao M, Franqui-Machin R, Xu H. NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma. Leukemia. 2017; 31(7):1648-1650.","DOI":"10.1038\/leu.2017.115"},{"key":"68585","doi-asserted-by":"crossref","unstructured":"Franqui-Machin R, Hao M, Bai H. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest. 2018; 128(7):2877-2893.","DOI":"10.1172\/JCI98765"},{"key":"68586","doi-asserted-by":"crossref","unstructured":"Kuiper R, Broyl A, de Knegt Y. A gene expression signature for high-risk multiple myeloma. Leukemia. 2012; 26(11):2406-2413.","DOI":"10.1038\/leu.2012.127"},{"key":"68587","doi-asserted-by":"crossref","unstructured":"Steiert B, Timmer J, Kreutz C. L1 regularization facilitates detection of cell type-specific parameters in dynamical systems. Bioinformatics. 2016; 32(17):i718-i726.","DOI":"10.1093\/bioinformatics\/btw461"},{"key":"68588","doi-asserted-by":"crossref","unstructured":"Zhan F, Huang Y, Colla S. The molecular classification of multiple myeloma. Blood. 2006; 108(6):2020-2028.","DOI":"10.1182\/blood-2005-11-013458"},{"key":"68589","doi-asserted-by":"crossref","unstructured":"Yang T, Qian Y, Liang X. LILRB4, an immune checkpoint on myeloid cells. Blood Sci. 2022; 4(2):49-56.","DOI":"10.1097\/BS9.0000000000000109"},{"key":"68590","doi-asserted-by":"crossref","unstructured":"Wang J, Zhang X, Zhou Z. A novel adoptive synthetic TCR and antigen receptor (STAR) T-cell therapy for B-cell acute lymphoblastic leukemia. Am J Hematol. 2022; 97(8):992-1004.","DOI":"10.1002\/ajh.26586"},{"key":"68591","doi-asserted-by":"crossref","unstructured":"Bancaro N, Cal\u00ec B, Troiani M. Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. Cancer Cell. 2023; 41(3):602-619.","DOI":"10.1016\/j.ccell.2023.02.004"},{"key":"68592","doi-asserted-by":"crossref","unstructured":"Deng M, Gui X, Kim J. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018; 562(7728):605-609.","DOI":"10.1038\/s41586-018-0615-z"},{"key":"68593","doi-asserted-by":"crossref","unstructured":"Zurli V, Wimmer G, Cattaneo F. Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia. Blood. 2017; 130(18):2006-2017.","DOI":"10.1182\/blood-2017-03-775858"},{"key":"68594","doi-asserted-by":"crossref","unstructured":"Li J, Gao A, Zhang F. ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer. Cancer Lett. 2021; 501:263-276.","DOI":"10.1016\/j.canlet.2020.10.048"},{"key":"68595","doi-asserted-by":"crossref","unstructured":"Di Meo F, Iyer A, Akama K. A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma. Cell Rep Med. 2023; 4(7):101110.","DOI":"10.1016\/j.xcrm.2023.101110"},{"key":"68596","doi-asserted-by":"crossref","unstructured":"Sun Z, Ji J, Li Y. Identification of evolutionary mechanisms of myelomatous effusion by single-cell RNA sequencing. Blood Adv. 2023; 7(15):4148-4159.","DOI":"10.1182\/bloodadvances.2022009477"},{"key":"68597","doi-asserted-by":"crossref","unstructured":"Yu T, Du C, Ma X. Polycomb-like protein 3 induces proliferation and drug resistance in multiple myeloma and is regulated by miRNA-15a. Mol Cancer Res. 2020; 18(7):1063-1073.","DOI":"10.1158\/1541-7786.MCR-19-0852"},{"key":"68598","doi-asserted-by":"crossref","unstructured":"Wei X, Yu Z, Tang P. Multiple myeloma-derived miR-27b-3p facilitates tumour progression via promoting tumour cell proliferation and immunosuppressive microenvironment. Clin Transl Med. 2023; 13(1):e1140.","DOI":"10.1002\/ctm2.1140"},{"key":"68599","doi-asserted-by":"crossref","unstructured":"Li K, Shi H, Zhang B. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021; 6(1):362.","DOI":"10.1038\/s41392-021-00670-9"},{"key":"68600","doi-asserted-by":"crossref","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021; 21(8):485-498.","DOI":"10.1038\/s41577-020-00490-y"},{"key":"68601","doi-asserted-by":"crossref","unstructured":"Wang D, Wang J, Hu G. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/ refractory multiple myeloma. Blood. 2021; 137(21):2890-2901.","DOI":"10.1182\/blood.2020008936"},{"key":"68602","doi-asserted-by":"crossref","unstructured":"Mailankody S, Devlin SM, Landa J. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022; 387(13):1196-1206.","DOI":"10.1056\/NEJMoa2209900"},{"key":"68603","doi-asserted-by":"crossref","unstructured":"Lee LSH, Yong KL. BCMA CARs in multiple myeloma: room for more?. Blood. 2021; 137(21):2859-2860.","DOI":"10.1182\/blood.2021010833"},{"key":"68604","doi-asserted-by":"crossref","unstructured":"van de Donk N, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021; 8(6):e446-e461.","DOI":"10.1016\/S2352-3026(21)00057-0"},{"key":"68605","doi-asserted-by":"crossref","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023; 20(6):359-371.","DOI":"10.1038\/s41571-023-00754-1"},{"key":"68606","doi-asserted-by":"crossref","unstructured":"Raje N, Berdeja J, Lin Y. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019; 380(18):1726-1737.","DOI":"10.1056\/NEJMoa1817226"},{"key":"68607","doi-asserted-by":"crossref","unstructured":"Smith EL, Harrington K, Staehr M. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019; 11(485):eaau7746.","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"68608","doi-asserted-by":"crossref","unstructured":"Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021; 18(2):71-84.","DOI":"10.1038\/s41571-020-0427-6"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285099\/77107","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285099\/77709","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11626\/77107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:31Z","timestamp":1794045991000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":56,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285099","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}